August 5, 2010 Cynapsus Announces Formation of Clinical Advisory Board For Parkinson’s Program Read More >		August 4, 2010 Cynapsus Announces Additional Debenture Financing Read More >
		July 29, 2010 Cynapsus Announces Addition of Dr. Albert Agro to Parkinson’s Program Team Read More >		July 27, 2010 Cynapsus Announces Parkinson’s Disease Survey Results Read More >
		July 26, 2010 Cynapsus Announces Signing of License Option Agreement of Parkinson’s Disease Technology Read More >		July 19, 2010 Cynapsus Announces Debenture Financing Read More >
				Press Release Archive

Cynapsus Therapeutics is a specialty clinical development pharmaceutical company targeting diseases of the brain. Cynapsus has a lower risk Parkinson's drug candidate ("APL-130277"), which is a reformulation of an approved drug. APL-130277 is designed to address a much larger moderate to severe patient population, which represents close to 50% of Parkinson's patients. Download Recent Survey Results here.